2023
Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City
Pandey A, Fitzpatrick M, Moghadas S, Vilches T, Ko C, Vasan A, Galvani A. Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City. The Lancet Regional Health - Americas 2023, 24: 100555. PMID: 37554154, PMCID: PMC10405058, DOI: 10.1016/j.lana.2023.100555.Peer-Reviewed Original ResearchHealthcare costsVaccine dosesInfluenza vaccine coverageCOVID-19 illnessDirect healthcare costsSevere health outcomesCOVID-19 vaccineCOVID-19 burdenNew York CityBooster vaccineVaccine coverageVaccination ratesBivalent vaccineBase case scenarioHealth outcomesEligible residentsProbable casesDisease controlVaccineCanadian InstituteCOVID-19VaccinationHealth researchCommonwealth FundOutcomes
2022
Return on Investment of the COVID-19 Vaccination Campaign in New York City
Sah P, Vilches T, Moghadas S, Pandey A, Gondi S, Schneider E, Singer J, Chokshi D, Galvani A. Return on Investment of the COVID-19 Vaccination Campaign in New York City. JAMA Network Open 2022, 5: e2243127. PMID: 36409495, PMCID: PMC9679875, DOI: 10.1001/jamanetworkopen.2022.43127.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccination campaignVaccination campaignIntensive care unit admissionCare unit admissionEmergency department visitsIndirect costsDecision analytical modelEmergency medical servicesCOVID-19 deathsHealth care expendituresUnit admissionDepartment visitsFuture COVID-19 outbreaksNew York CityOutpatient visitsVaccine uptakeSevere outcomesVaccination programPotential yearsMAIN OUTCOMEVaccinationHealth outcomesProbable casesSocietal perspectiveCare expendituresQuarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19
Wells CR, Pandey A, Gokcebel S, Krieger G, Donoghue AM, Singer BH, Moghadas SM, Galvani AP, Townsend JP. Quarantine and serial testing for variants of SARS-CoV-2 with benefits of vaccination and boosting on consequent control of COVID-19. PNAS Nexus 2022, 1: pgac100. PMID: 35909795, PMCID: PMC9335027, DOI: 10.1093/pnasnexus/pgac100.Peer-Reviewed Original ResearchSARS-CoV-2Serial testingSerial testing strategyHigh population immunityQuarantine durationBenefits of vaccinationSARS-CoV-2 variantsDisease time courseCOVID-19CoV-2 variantsPublic health toolVaccine boostingThird doseVaccination statusVaccination coveragePopulation immunityCoV-2Health toolsDisease control effortsInfected casesLocal transmissionInfectiousness profileVaccinationTime courseImmunityModeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
Du Z, Wang L, Pandey A, Lim WW, Chinazzi M, Piontti APY, Lau EHY, Wu P, Malani A, Cobey S, Cowling BJ. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nature Medicine 2022, 28: 934-938. PMID: 35210596, PMCID: PMC9117137, DOI: 10.1038/s41591-022-01736-z.Peer-Reviewed Original ResearchConceptsLarge-scale survey dataEconomic benefitsFull dose vaccinationSurvey dataHospital admission costsDose-sparing strategiesCost of hospitalizationCOVID-19 deathsPopulation-level transmissionVaccine dosesVaccination strategiesAdmission costsEconomic burdenVaccine shortageFractional dosesVaccinationDose fractionationHigh transmissibilityVaccine distributionCostPublic healthVaccineWillingnessDosesIndia
2020
Prosocial polio vaccination in Israel
Wells CR, Huppert A, Fitzpatrick MC, Pandey A, Velan B, Singer BH, Bauch CT, Galvani AP. Prosocial polio vaccination in Israel. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 13138-13144. PMID: 32457142, PMCID: PMC7293608, DOI: 10.1073/pnas.1922746117.Peer-Reviewed Original ResearchConceptsOral polio vaccineOPV campaignsPolio vaccineVaccination behaviorInactivated polio vaccineGreater vaccination coverageRisk of paralysisProsocial vaccinationVaccination coverageVaccine campaignPolio vaccinationVaccinationInsufficient vaccinationPoliomyelitis eradicationSurveillance programVaccineSporadic outbreaksIsrael MinistryPrimary objectiveProsocial natureParalysisDiseasePolio
2019
The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo
Wells CR, Pandey A, Mbah M, Gaüzère BA, Malvy D, Singer BH, Galvani AP. The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 24366-24372. PMID: 31636188, PMCID: PMC6883813, DOI: 10.1073/pnas.1913980116.Peer-Reviewed Original ResearchConceptsCase isolationEbola treatment centersPopulation-level effectivenessPublic health responseHealthcare workersVaccination effortsTreatment centersHealth responseEbola transmissionInfectious diseasesEpidemic trajectoriesEbola outbreakDisease transmissionIncidenceEpidemicTemporal incidenceDemocratic RepublicExacerbationVaccinationDiseaseEbola vaccination in the Democratic Republic of the Congo
Wells CR, Pandey A, Parpia AS, Fitzpatrick MC, Meyers LA, Singer BH, Galvani AP. Ebola vaccination in the Democratic Republic of the Congo. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 10178-10183. PMID: 31036657, PMCID: PMC6525480, DOI: 10.1073/pnas.1817329116.Peer-Reviewed Original ResearchConceptsContacts of casesImpact of vaccinationFrontline healthcare workersEbola vaccinationEbola vaccineVaccination programHealthcare workersLong-range disseminationVaccination campaignCase confirmationEbola transmissionHigh-risk regionsEbola riskVaccinationFuture outbreaksRiskEarly implementationEbolaLevel of riskDemocratic RepublicGlobal spreadOutbreakVaccineInfectionDoses
2016
One Health approach to cost-effective rabies control in India
Fitzpatrick MC, Shah HA, Pandey A, Bilinski AM, Kakkar M, Clark AD, Townsend JP, Abbas SS, Galvani AP. One Health approach to cost-effective rabies control in India. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 14574-14581. PMID: 27994161, PMCID: PMC5187709, DOI: 10.1073/pnas.1604975113.Peer-Reviewed Original ResearchConceptsHuman rabiesRabies deathsCanine vaccinationStray dogsHuman rabies deathsRabies controlCost-effectiveness thresholdPostexposure vaccinationWHO criteriaDog bitesAutopsy dataHealth outcomesHealth approachSurveillance dataVaccinationCost-effective strategyDogsRabiesRabies surveillance dataOne-third